The Clinical Study Of Therapeutic Effects And Mechanism Of Huganjiexian Decoction On Hepatic Cirrhosis

ObjectiveTo observe the clinical therapeutic effects of Huganjiexian decoction、investigatethe mechanism of this decoction and evaluate the security of it on patients withhepatic cirrhosis.MethodsAccording to the inclusion criteria,72patients with liver cirrhosis were dividedinto experimental group and control group by the principles of random andcomparison. The control group was only treated with conventional therapy while theexperiment group was treated with Huganjiexian decoction combined withconventional therapy. The therapeutic course of each group was6months. At thebeginning of treatment and2,4,6months after treatment, the indictors of liverfunction, renal function, blood conagulate time, blood routine test, urine examinationwere examined. At the beginning of treatment and3,6months after treatment, theindictors of hepatitis B virus (HBV), alpha fetoprotein(AFP), HBV-DNA, abdominalB-ultrasound were examined. At the beginning of treatment and6months aftertreatment, liver stiffness measurement(LSM), platelet-derived growth factor-BB(PDGF-BB) and transforming growth factor-β1(TGF-β1) were examined.Results1. There were no significant differences of the indictors of liver function, renalfunction, blood routine test, urine examination, blood conagulate time, the indictors of liver fibrosis, abdominal B-ultrasound、HBV-DNA, AFP, LSM, PDGF-BB andTGF-β1by two independent-samples t test between two groups before treatment.Those indicated two groups had consistency and comparability.2. With the way of repeated measures analysis of variance, the indictors ofliver function in two groups improved after treatment; the indictors of liver functionin the experimental group were better than that of the control group；the indictors ofliver fibrosis, LSM, PDGF-BB, TGF-β1decreased in two groups after treatment. Thedownward trends of the indictors of liver fibrosis, LSM, PDGF-BB, TGF-β1of theexperimental group were more significant than those of the control group. AbdominalB-ultrasound, HBV-DNA improved in two groups after treatment, but the trends ofabdominal B-ultrasound, HBV-DNA were no significant difference between twogroups. There were no significant changes of renal function, blood routine test, urineexamination, blood conagulate time, AFP between two groups.Conclusions1. Huganjiexian decoction could protect liver function on hepatic cirrhosis.2. Huganjiexian decoction could treat hepatic fibrosis and hepatic cirrhosis.3. Huganjiexian decoction could prevent hepatic fibrosis by inhibiting thesecretion of serum PDGF-BB and TGF-β1.4. Huganjiexian decoction had no obvious side effects.